Lyophilized Product Market, By Drug Class (Anti-infective, Antineoplastic, Diuretics, Proton pump inhibitor, Anesthetic, Anticoagulant, NSAIDs, and Others), By Indication (Infectious Disease, Autoimmune Diseases, Gastrointestinal Diseases, Cancer, and Oth
Description
Lyophilized Product Market, By Drug Class (Anti-infective, Antineoplastic, Diuretics, Proton pump inhibitor, Anesthetic, Anticoagulant, NSAIDs, and Others), By Indication (Infectious Disease, Autoimmune Diseases, Gastrointestinal Diseases, Cancer, and Others), By Packaging Type (Vial, Syringes, and Cartridge), and By Region (North America, Latin America, Europe, Asia-Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2021 - 2028
Lyophilization or freeze drying is the process in which the water content in the drug sample is frozen, followed by its removal from the sample. In the process of lyophilization, the frozen water content changes directly from solid to vapor without passing through a liquid phase. The process includes three steps: freezing, primary drying (sublimation), and secondary drying (desorption). Pharmaceutical products that undergo lyophilization process include bulk pharmaceutical/biopharmaceutical ingredient, protein, collagen, peptide, oligonucleotide, enzymes, and mAbs (Monoclonal Antibody)
Market Dynamics
Key market players are focusing on increasing product launches and approvals, which is expected drive the growth of the market over forecast period. For instance, in May 2019, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., received the U.S. Food and Drug Administration (FDA) approval for a new dosage form (50 mg) and two new indications for pembrolizumab available as a lyophilized powder (Keytruda): Non–small-cell Lung Cancer (NSCLC) and Renal Cell Carcinoma (RCC). Additionally, in December 2020, Novartis AG, a global healthcare company, announced that the European Commission (EC) approved Xolair (omalizumab) as an add-on therapy with intranasal corticosteroids (INC) for the treatment of adults (18 years and above) with severe chronic rhinosinusitis with nasal polyps (CRSwNP), where therapy only with INC does not provide adequate disease control.
Key features of the study:
Lyophilization or freeze drying is the process in which the water content in the drug sample is frozen, followed by its removal from the sample. In the process of lyophilization, the frozen water content changes directly from solid to vapor without passing through a liquid phase. The process includes three steps: freezing, primary drying (sublimation), and secondary drying (desorption). Pharmaceutical products that undergo lyophilization process include bulk pharmaceutical/biopharmaceutical ingredient, protein, collagen, peptide, oligonucleotide, enzymes, and mAbs (Monoclonal Antibody)
Market Dynamics
Key market players are focusing on increasing product launches and approvals, which is expected drive the growth of the market over forecast period. For instance, in May 2019, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., received the U.S. Food and Drug Administration (FDA) approval for a new dosage form (50 mg) and two new indications for pembrolizumab available as a lyophilized powder (Keytruda): Non–small-cell Lung Cancer (NSCLC) and Renal Cell Carcinoma (RCC). Additionally, in December 2020, Novartis AG, a global healthcare company, announced that the European Commission (EC) approved Xolair (omalizumab) as an add-on therapy with intranasal corticosteroids (INC) for the treatment of adults (18 years and above) with severe chronic rhinosinusitis with nasal polyps (CRSwNP), where therapy only with INC does not provide adequate disease control.
Key features of the study:
- This report provides an in-depth analysis of the global lyophilized product market, market size (US$ Bn), and compound annual growth rate (CAGR%) for the forecast period (2021–2028), considering 2020 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global lyophilized product market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Sanofi, Merck & Co., Inc., Fresenius Kabi AG, Ciron Drugs & Pharmaceuticals Pvt. Ltd., Glaxosmithkline Plc, Mylan NV., Pfizer, Inc., Amneal Pharmaceuticals LLC, Otsuka Holdings Co. Ltd., BTG PLC, Bristol-Myers Squibb Company, Novartis AG, Takeda Pharmaceutical Company Limited, Biogen Inc., Dr. Reddy's Laboratories Ltd., Zydus Cadila, AbbVie Inc., Cipla Inc., Johnson & Johnson Services, Inc., Affy Pharma Private Limited, Jubilant Pharmova Limited, and Biocon
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global lyophilized product market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global lyophilized product market
- Global Lyophilized Product Market, By Drug Class:
- Anti-infective
- Antineoplastic
- Diuretics
- Proton pump inhibitor
- Anesthetic
- Anticoagulant
- NSAIDs
- Others
- Global Lyophilized Product Market, By Indication:
- Infectious Disease
- Autoimmune Diseases
- Gastrointestinal Diseases
- Cancer
- Others
- Global Lyophilized Product Market, Packaging Type:
- Vial
- Syringes
- Cartridge
- Global Lyophilized Product Market, By Region:
- North America
- By Drug Class
- Anti-infective
- Antineoplastic
- Diuretics
- Proton pump inhibitor
- Anesthetic
- Anticoagulant
- NSAID's
- Others
- By Indication
- Infectious Disease
- Autoimmune Diseases
- Gastrointestinal Diseases
- Cancer
- Others
- By Packaging Type
- Vial
- Syringes
- Cartridge
- By Country
- U.S.
- Canada
- Latin America
- By Drug Class
- Anti-infective
- Antineoplastic
- Diuretics
- Proton pump inhibitor
- Anesthetic
- Anticoagulant
- NSAID's
- Others
- By Indication
- Infectious Disease
- Autoimmune Diseases
- Gastrointestinal Diseases
- Cancer
- Others
- By Packaging Type
- Vial
- Syringes
- Cartridge
- By Country
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- By Drug Class
- Anti-infective
- Antineoplastic
- Diuretics
- Proton pump inhibitor
- Anesthetic
- Anticoagulant
- NSAID's
- Others
- By Indication
- Infectious Disease
- Autoimmune Diseases
- Gastrointestinal Diseases
- Cancer
- Others
- By Packaging Type
- Vial
- Syringes
- Cartridge
- By Country
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- By Drug Class
- Anti-infective
- Antineoplastic
- Diuretics
- Proton pump inhibitor
- Anesthetic
- Anticoagulant
- NSAID's
- Others
- By Indication
- Infectious Disease
- Autoimmune Diseases
- Gastrointestinal Diseases
- Cancer
- Others
- By Packaging Type
- Vial
- Syringes
- Cartridge
- By Country
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- By Drug Class
- Anti-infective
- Antineoplastic
- Diuretics
- Proton pump inhibitor
- Anesthetic
- Anticoagulant
- NSAID's
- Others
- By Indication
- Infectious Disease
- Autoimmune Diseases
- Gastrointestinal Diseases
- Cancer
- Others
- By Packaging Type
- Vial
- Syringes
- Cartridge
- By Country
- GCC
- Israel
- Rest of Middle East
- Africa
- By Drug Class
- Anti-infective
- Antineoplastic
- Diuretics
- Proton pump inhibitor
- Anesthetic
- Anticoagulant
- NSAID's
- Others
- By Indication
- Infectious Disease
- Autoimmune Diseases
- Gastrointestinal Diseases
- Cancer
- Others
- By Packaging Type
- Vial
- Syringes
- Cartridge
- By Region/Country
- South Africa
- Central Africa
- North Africa
- Company Profiles
- Sanofi*
- Company Highlights
- Product Types Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Merck & Co., Inc.
- Fresenius Kabi AG
- Ciron Drugs & Pharmaceuticals Pvt. Ltd
- Glaxosmithkline Plc
- Mylan NV.
- Pfizer, Inc.
- Amneal Pharmaceuticals LLC
- Otsuka Holdings Co. Ltd.
- BTG PLC
- Bristol-Myers Squibb Company
- Novartis AG
- Takeda Pharmaceutical Company Limited
- Biogen Inc.
- Dr. Reddy's Laboratories Ltd.
- Zydus Cadila
- AbbVie Inc.
- Cipla Inc.
- Johnson & Johnson Services, Inc.
- Affy Pharma Private Limited
- Jubilant Pharmova Limited
- Biocon
Table of Contents
326 Pages
- 1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
- 2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Drug Class
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
- 3. Market Dynamics, Regulations, and Trends Analysis
- Drivers
- Restraints
- Opportunities
- Impact Analysis
- Pipeline Analysis
- Regulatory Scenario
- Recent Product Approval/Launch
- PEST Analysis
- Epidemiology
- 4. Global Eosinophilic Esophagitis Market – Impact of Coronavirus (COVID-19) Pandemic
- COVID-19 Epidemiology
- Supply and Demand Analysis
- Key Developments
- 5. Global Eosinophilic Esophagitis Market , By Drug Class, 2017 – 2028, (US$ Mn)
- Introduction
- Market Share Analysis, 2021 and 2028 (%)
- Y-o-Y Growth Analysis, 2017 – 2028
- Segment Trends
- Corticosteroids
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
- Budesonide
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
- • Jorveza
- 1. Introduction
- 2. Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
- • Off-label budesonide
- 1. Introduction
- 2. Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
- Fluticasone
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
- Proton Pump Inhibitor (PPI)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
- Omeprazole
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
- Esomeprazole
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
- Late Stage Pipeline Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
- Dupixent
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
- APT-1011
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
- Lirentelimab (AK002)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
- Cendakimab
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
- Etrasimod
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
- TAK-721
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
- Omilancor (BT-11)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
- 6. Global Eosinophilic Esophagitis Market, By Distribution Channel, 2017 – 2028, (US$ Mn)
- Introduction
- Market Share Analysis, 2021 and 2028 (%)
- Y-o-Y Growth Analysis, 2017 – 2028
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
- 7. Global Eosinophilic Esophagitis Market, By Region, 2017 – 2028, (US$ Mn)
- Introduction
- Market Share Analysis, By Region, 2021 and 2028 (%)
- Y-o-Y Growth Analysis, For Regions, 2017–2028
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 – 2028, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 – 2028, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2028, (US$ Mn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 – 2028, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 – 2028, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2028, (US$ Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 – 2028, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 – 2028, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2028, (US$ Mn)
- U.K.
- Germany
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 – 2028, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 – 2028, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2028, (US$ Mn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 – 2028, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 – 2028, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2028, (US$ Mn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 – 2028, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 – 2028, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2017 – 2028, (US$ Mn)
- North Africa
- Central Africa
- South Africa
- 8. Competitive Landscape
- Heat Map Analysis
- Market Share Analysis
- Ellodi Pharmaceuticals.
- Company Highlights
- Product Portfolio
- Key Highlights
- Strategies
- EsoCap AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Strategies
- GlaxoSmithKline plc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Teva Pharmaceutical Industries Ltd
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Cipla Limited
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Sun Pharmaceutical Industries Limited
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- AstraZeneca Plc
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Sanofi S.A.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Arena Pharmaceuticals, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Strategies
- Takeda Pharmaceutical Company Limited
- Company Highlights
- Product Portfolio
- Key Highlights
- Strategies
- Revolo Biotherapeutics
- Company Highlights
- Product Portfolio
- Key Highlights
- Strategies
- Allakos Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Strategies
- Bristol-Myers Squibb Co
- Company Highlights
- Product Portfolio
- Key Highlights
- Strategies
- Calypso Biotech
- Company Highlights
- Product Portfolio
- Key Highlights
- Strategies
- DBV Technologies
- Company Highlights
- Product Portfolio
- Key Highlights
- Strategies
- Landos Biopharma, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Strategies
- Glenmark Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Alkem Laboratories Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Quorum Innovations LLC
- Company Highlights
- Product Portfolio
- Key Highlights
- Strategies
- Dr. Falk Pharma GmbH
- Company Highlights
- Product Portfolio
- Key Highlights
- Strategies
- Analyst Views
- 9. Section
- Research Methodology
- About us
- *Browse 29 Market Data Tables and 38 Figures on "Global Eosinophilic Esophagitis Market” - Global forecast to 2028
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
